Semaglutide, 0.5 mg/mL

DRUG4 trials

Sponsors

Novo Nordisk A/S, University of Oxford, Bispebjerg Hospital, Chinese University of Hong Kong

Conditions

Cognitive ChangeDiabetes Mellitus, Type 2Intracerebral HemorrhageKidney Disease, Chronic

Phase 1

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

CompletedNCT03598621

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-07-23End: 2019-01-17Updated: 2020-01-09

Phase 2

GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial

Not yet recruitingNCT07613437

Chinese University of Hong KongIntracerebral Hemorrhage

Start: 2026-06-15End: 2028-12-31Target: 200Updated: 2026-05-29

Unknown Phase

Semaglutide and Cognition in Healthy Volunteers

CompletedNCT06363487

University of OxfordCognitive Change

Start: 2024-06-06End: 2024-12-11Updated: 2025-06-06

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

Not yet recruitingNCT06555146

Bispebjerg HospitalDiabetes Mellitus, Type 2, Kidney Disease, Chronic

Start: 2024-08-31End: 2025-03-31Target: 15Updated: 2024-08-15